What the Raising the Bar research exemption means for biotech
15 June, 2012 by Tim DeanThe research exemption in the new Raising the Bar bill allows experimentation on patented processes, but the line between what is permitted and what is infringing a patent is not yet fully clear.
PIC reports to Ministers on treatment of similar biologics
14 June, 2012 by AusBiotechThe Pharmaceuticals Industry Council (PIC), with members AusBiotech, Medicines Australia and the GMiA, has reported to the Federal Government on the preferred treatment of follow-on biologics for reimbursement.
ResMed launches sleep apnoea device in US
14 June, 2012 by Dylan Bushell-EmblingResMed (ASX:RMD) has brought Narval CC, an alternative treatment to PAP therapy for snoring and sleep apnoea, to the US market.
Opinion: The brutal truth about innovation in Australia
14 June, 2012 by Staff WritersDr Rowan Gilmore, CEO of the Australian Institute for Commercialisation, wonders whether Australian government and business are truly hungry enough to drive innovation in this country.
CSL gets orphan drug status for haemophilia-B treatment
13 June, 2012 by Dylan Bushell-EmblingCSL's (ASX:CSL) plasma protein unit, CSL Behring, has received US FDA orphan drug designation for a haemophilia-B treatment, rIX-FP.
NIH puts $4.5m into superbug killers
13 June, 2012 by Tim DeanThe Monash Institute of Phermaceutical Sciences has received a $4.48 million grant from the US National Institutes of Health to develop new antibiotics to combat multidrug-resistant bacteria.
Universal Biosensors to get $1.5m from Siemens
12 June, 2012 by Dylan Bushell-EmblingUniversal Biosensors (ASX:UBI) has achieved the first of six milestones under its coagulation testing collaboration with Siemens Healthcare Diagnostics.
ImpediMed wins “Life Changing Technology” award
12 June, 2012 by AusBiotechImpediMed Limited (ASX:IPD) has been recognised for making “the biggest difference on an individual while addressing the greatest medical need” for its bioelectrical impedance analysis (BIA) technology.
Pharmaxis debuts Bronchitol in EU
08 June, 2012 by Dylan Bushell-EmblingPharmaxis (ASX:PXS) has officially launched its Bronchitol spray in the UK and Germany, and presented more trial data showing its efficacy.
Mesoblast to push development of dental pulp stem cells
08 June, 2012 by Dylan Bushell-EmblingMesoblast's (ASX:MSB) CEO has detailed plans to work with partner Teva to commercialise off-the-shelf adult dental pulp stem cells (DPSCs) for neurological conditions.
Prima BioMed’s incoming CEO to refocus company on CVac
08 June, 2012 by Tim DeanIncoming CEO and present COO of Prima BioMed, Matt Lehman, will refocus the company’s efforts on progressing CVac through clinical trials.
pSivida microdrug patent paves way for Medidur
07 June, 2012 by Dylan Bushell-EmblingpSivida (ASX:PVA) has received a US patent for a new microdrug delivery device which will be used with its Medidur implant, an injectable, sustained-release drug delivery system.
New WA AusBiotech industry development officer appointed
07 June, 2012 by AusBiotechAusBiotech members in Western Australia (WA) this week welcome the appointment of a new industry development officer (IDO), Michelle Nicolson to support the work of the WA Branch Committee.
BioDiem sets sights on dengue fever vaccine
07 June, 2012 by Dylan Bushell-EmblingBioDiem (ASX:BDM) has been granted a license for vaccine technology developed at ANU with applications for diseases including dengue fever.
AHG files for CE Mark for heart patch
05 June, 2012 by Dylan Bushell-EmblingAllied Healthcare (ASX:AHZ) has lodged an application for a CE Mark for CardioCel, the cardiovascular patch developed by subsidiary Celxel.
